What type of drug does obeticholic acid belong to?

Obeticholic acid(Obeticholic acid) is a new synthetic bile acid derivative that belongs to the agonist class of Farnesoid X Receptor (FXR) agonists. FXR is a nuclear receptor found in the liver, small intestine, kidneys and adrenal glands. It is mainly involved in the synthesis, transport, excretion and homeostasis regulation of bile acids. As a potent and selective agonist of this receptor, obeticholic acid fundamentally intervenes in bile acid metabolism disorders by regulating the FXR-mediated signaling pathway, thereby exerting its pharmacological effect in the treatment of cholestatic diseases. As a chemical analog of endogenous bile acids, obeticholic acid can simulate natural bile acids and bind to FXR, thereby inhibiting the expression of cholesterol 7α-hydroxylase (CYP7A1), a key enzyme in bile acid biosynthesis, reducing the production of excess bile acids, while promoting their transport and excretion.

Structurally, obeticholic acid is a semi-synthetic derivative of chenodeoxycholic acid (CDCA), a natural bile acid in the human body. Through the optimized modification of the molecular structure, it has achieved higher receptor affinity and stronger activity than CDCA, and can exert more significant biological effects at a lower dose. This mechanism of action makes it one of the current first-line options for the treatment of primary biliary cholangitis (PBC), especially for patients who have insufficient response to or intolerance to the conventional treatment drug ursodeoxycholic acid (UDCA). In addition to its application in PBC, obeticholic acid also shows good therapeutic prospects in the field of chronic liver diseases such as non-alcoholic steatohepatitis (NASH). It is currently in multiple global clinical research stages, and its research directions cover various pathological processes such as liver fibrosis, hepatic steatosis and metabolic disorders.

Therefore, from the perspective of drug taxonomy, obeticholic acid is one of the nuclear receptor modulatorsFXR agonists, which can also be classified as bile acid analogues for the treatment of liver diseases. Its mechanism of action is based on molecular biology, represents the development direction of precision medicine and targeted therapy, and provides new treatment strategies and possibilities for many cholestatic and metabolic liver diseases.

Reference materials:https://en.wikipedia.org/wiki/Obeticholic_acid